clopidogrel (SR25990C)

DRUG4 trials

Sponsors

Sanofi

Conditions

Atrial FibrillationCerebral InfarctionNSTEACSPlatelet Aggregation InhibitorsVascular Risk

Phase 3

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

TerminatedNCT00243178

SanofiAtrial Fibrillation, Vascular Risk

Start: 2003-07-31End: 2005-09-30Updated: 2009-10-19

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

CompletedNCT00249873

SanofiAtrial Fibrillation, Vascular Risk

Start: 2003-06-30End: 2009-03-31Updated: 2015-06-15

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

CompletedNCT00325390

SanofiNSTEACS, Platelet Aggregation Inhibitors

Start: 2004-07-31Target: 800Updated: 2009-03-25

Phase 4

Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment

CompletedNCT00386191

SanofiCerebral Infarction

Start: 2006-09-30End: 2008-12-31Updated: 2010-02-24

Related Papers

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

2010-08-29369 citations

Cognitive function and anticoagulation control in patients with atrial fibrillation.

2010-03-1687 citations

Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

2009-03-31695 citations

Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.

2007-11-13308 citations

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

2006-06-011241 citations